Skip to main content
SpringerLink
Log in

Psychotropic Drug-Induced Disordered Eating Behaviors

  • Chapter
  • First Online:
Hidden and Lesser-known Disordered Eating Behaviors in Medical and Psychiatric Conditions

  • 1089 Accesses

Abstract

The influence of drugs on body weight and food drive is complex and intriguing. Multiple brain areas are involved in the regulation of eating behaviors, and psychotropic drugs can play a role in this regard. The dopaminergic activity of many medications has to do also with the complex mechanisms of reward in the brain. While prescribing a psychotropic drug, its effects on body weight and appetite should be carefully considered. Weight gain could determine reduced compliance to therapy, especially for those patients who present a comorbid eating disorder or have a history of overweight or obesity. Similarly, medications that cause weight loss could be used by patients as a pathological way to control their weight. This chapter will focus on those psychotropic agents that increase and decrease appetite and weight.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73(9):904–14.

    Article  PubMed  PubMed Central  Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. 2013. https://doi.org/10.1176/appi.books.9780890425596.744053.

  3. Trinko R, Sears RM, Guarnieri DJ, DiLeone RJ. Neural mechanisms underlying obesity and drug addiction. Physiol Behav. 2007;91(5):499–505. Epub 2007 Jan 16.

    Article  CAS  PubMed  Google Scholar 

  4. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4):e94112. https://doi.org/10.1371/journal.pone.0094112.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med. 2010;40:187–200.

    Article  CAS  PubMed  Google Scholar 

  6. Nielsen MØ, Rostrup E, Wulff S, Glenthøj B, Ebdrup BH. Striatal reward activity and antipsychotic-associated weight change in patients with schizophrenia undergoing initial treatment. JAMA Psychiat. 2016;73:121–8.

    Article  Google Scholar 

  7. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41.

    Article  CAS  PubMed  Google Scholar 

  8. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther. 2010;127:210–51. https://doi.org/10.1016/j.pharmthera.2010.04.008.

    Article  CAS  PubMed  Google Scholar 

  9. Albaugh VL, Singareddy R, Mauger D, Lynch CJ. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One. 2011;6:e22662.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Takeuchi Y, Kajiyama K, Ishiguro C, Uyama Y. Atypical antipsychotics and the risk of hyperlipidemia: a sequence symmetry analysis. Drug Saf. 2015;38:641–50.

    Article  CAS  PubMed  Google Scholar 

  11. Potvin S, Zhornitsky S, Stip E. Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Can J Psychiatry. 2015;60:S26.

    PubMed  PubMed Central  Google Scholar 

  12. Zhang Q, Deng C, Huang XF. The role of ghrelin signalling in second-generation antipsychotic-induced weight gain. Psychoneuroendocrinology. 2013;38(11):2423–38. https://doi.org/10.1016/j.psyneuen.2013.07.010. Epub 2013 Aug 14. Review.

    Article  CAS  PubMed  Google Scholar 

  13. Kanji S, Fonseka TM, Marshe VS, Sriretnakumar V, Hahn MK, Müller DJ. The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain. Eur Arch Psychiatry Clin Neurosci. 2018;268:3–15.

    Article  CAS  PubMed  Google Scholar 

  14. Bond DJ, Kauer-Sant’Anna M, Lam RW, Yatham LN. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). J Affect Disord. 2010;124(1–2):108–17. https://doi.org/10.1016/j.jad.2009.10.023. Epub 2009 Nov 14

    Article  PubMed  Google Scholar 

  15. Kanemura H, Sano F, Maeda Y, Sugita K, Aihara M. Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy. Seizure. 2012;21(7):496–500. https://doi.org/10.1016/j.seizure.2012.05.001. Epub 2012 Jun 12

    Article  PubMed  Google Scholar 

  16. Torrent C, Amann B, Sanchez-Moreno J, Colom F, Reinares M, Comes M, Rosa AR, Scott J, Vieta E. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118:4–18.

    Article  CAS  PubMed  Google Scholar 

  17. McElroy SL, Keck PE Jr. Obesity in bipolar disorder: an overview. Curr Psychiatry Rep. 2012;14:650–8.

    Article  PubMed  Google Scholar 

  18. McElroy SL, Crow S, Cuellar-Barboza AB, Prieto ML, Veldic M, Winham SJ, Bobo WV, Geske J, Seymour LR, Mori N, Bond DJ, Biernacka JM, Frye MA. Clinical features of bipolar spectrum with binge eating behaviour. J Affect Disord. 2016;201:95–8.

    Article  PubMed  Google Scholar 

  19. Uguz F, Sahingoz M, Gungor B, Aksoy F, Askin R. Weight gain and associated factors in patients using newer antidepressant drugs. Gen Hosp Psychiatry. 2015;37(1):46–8. https://doi.org/10.1016/j.genhosppsych.2014.10.011. Epub 2014 Oct 31

    Article  PubMed  Google Scholar 

  20. McElroy SL, Guerdjikova AI, Mori N, Keck PE. Managing comorbid obesity and depression through clinical pharmacotherapies. Expert Opin Pharmacother. 2016;17(12):1599–610.

    Article  CAS  PubMed  Google Scholar 

  21. Kirkham T. Endocannabinoids and the neurochemistry of gluttony. J Neuroendocrinol. 2008;20:1099–100.

    Article  CAS  PubMed  Google Scholar 

  22. Hirsch S, Tam J. Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome. Toxins. 2019;11:275.

    Article  CAS  PubMed Central  Google Scholar 

  23. Tarragon E, Moreno JJ. Cannabinoids, chemical senses, and regulation of feeding behavior. Chem Senses. 2019;44(2):73–89. https://doi.org/10.1093/chemse/bjy068.

    Article  CAS  PubMed  Google Scholar 

  24. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 2011;95:189–99.

    Article  CAS  PubMed  Google Scholar 

  25. Kushner RF. Weight loss strategies for treatment of obesity: lifestyle management and pharmacotherapy. Prog Cardiovasc Dis. 2018;61:246–52.

    Article  PubMed  Google Scholar 

  26. Arterburn D, Sofer T, Boudreau DM, Bogart A, Westbrook EO, Theis MK, Simon G, Haneuse S. Long-term weight change after initiating second-generation antidepressants. J Clin Med. 2016;5(4)

    Google Scholar 

  27. Serralde-Zúñiga AE, Gonzalez Garay AG, Rodríguez-Carmona Y, Melendez G. Fluoxetine for adults who are overweight or obese. Cochrane Database Syst Rev. 2019;10:CD011688. https://doi.org/10.1002/14651858.CD011688.pub2. [Epub ahead of print] Review.

    Article  PubMed  Google Scholar 

  28. Krentz AJ, Fujioka K, Hompesch M. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes Obes Metab. 2016;18(6):558–70. https://doi.org/10.1111/dom.12657. Review.

    Article  CAS  PubMed  Google Scholar 

  29. Fulp A, Zhang Y, Bortoff K, Seltzman H, Snyder R, Wiethe R, Amato G, Maitra R. Pyrazole antagonists of the CB1 receptor with reduced brain penetration. Bioorg Med Chem. 2016;24:1063–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Saunders KH, Umashanker D, Igel LI, Kumar RB, Aronne LJ. Obesity pharmacotherapy. Med Clin North Am. 2018;102(1):135–48.

    Article  PubMed  Google Scholar 

  31. Amodeo G, Cuomo A, Bolognesi S, Goracci A, Trusso MA, Piccinni A, Neal SM, Baldini I, Federico E, Taddeucci C, Fagiolini A. Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice. Expert Opin Pharmacother. 2019;20(6):679–90. https://doi.org/10.1080/14656566.2019.1571041. Epub 2019 Jan 29. Review.

    Article  CAS  PubMed  Google Scholar 

  32. Bernet VJ. Thyroid hormone misuse and abuse. Endocrine. 2019;66:79–86.

    Article  CAS  PubMed  Google Scholar 

  33. Cochrane C, Malcolm R, Brewerton T. The role of weight control as a motivation for cocaine abuse. Addict Behav. 1998;23(2):201–7.

    Article  CAS  PubMed  Google Scholar 

  34. Vicentic A, Jones DC. The CART (cocaine- and amphetamine-regulated transcript) system in appetite and drug addiction. J Pharmacol Exp Ther. 2007;320(2):499–506. Epub 2006 Jul 13.

    Article  CAS  PubMed  Google Scholar 

  35. Ersche KD, Stochl J, Woodward JM, Fletcher PC. The skinny on cocaine: insights into eating behavior and body weight in cocaine-dependent men. Appetite. 2013;71:75–80. https://doi.org/10.1016/j.appet.2013.07.011. Epub 2013 Aug 3.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Neale J, Nettleton S, Pickering L, Fischer J. Eating patterns among heroin users: a qualitative study with implications for nutritional interventions. Addiction. 2012;107(3):635–41.

    Article  PubMed  Google Scholar 

  37. McIlwraith F, Betts KS, Jenkinson R, Hickey S, Burns L, Alati R. Is low BMI associated with specific drug use among injecting drug users? Subst Use Misuse. 2014;49(4):374–82.

    Article  PubMed  Google Scholar 

  38. Mysels DJ, Sullivan MA. The relationship between opioid and sugar intake: review of evidence and clinical applications. J Opioid Manag. 2010;6(6):445–52.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Pereska Z, Bozinovska C, Dimitrovski C, Cakalarovski K, Chibishev A, Zdravkovska M, Babulovska A, Janicevic D. Heroin dependence duration influences the metabolic parameters: mechanisms and consequences of impaired insulin sensitivity in hepatitis C virus seronegative heroin dependents. J Addict Med. 2012;6(4):304–10. https://doi.org/10.1097/ADM.0b013e31826bd76c.

    Article  CAS  PubMed  Google Scholar 

  40. Levine AS, Grace M, Billington CJ. The effect of centrally administered naloxone on deprivation and drug-induced feeding. Pharmacol Biochem Behav. 1990;36(2):409–12.

    Article  CAS  PubMed  Google Scholar 

  41. Peles E, Schreiber S, Sason A, Adelson M. Risk factors for weight gain during methadone maintenance treatment. Subst Abus. 2016;37(4):613–8.

    Article  PubMed  Google Scholar 

  42. Hu T, Yang Z, Li MD. Pharmacological effects and regulatory mechanisms of tobacco smoking effects on food intake and weight control. J Neuroimmune Pharmacol. 2018;13:453.

    Article  PubMed  Google Scholar 

  43. Chawla N, Charan D, Kumar S, Pattanayak RD. Pica associated with initiation of atypical antipsychotic drugs: Report of two cases. Psychiatry Clin Neurosci. 2016;70(8):363–4.

    Article  PubMed  Google Scholar 

  44. Huang JH, Shiah IS, Lee WK, Tzang RF, Chang KJ. Olanzapine-associated pica in a schizophrenia patient. Psychiatry Clin Neurosci. 2010;64(4):444.

    Article  PubMed  Google Scholar 

  45. Chawla N, Mandal P, Chatterjee B, Dhawan A. Tramadol-associated pica. Psychiatry Clin Neurosci. 2019;73(1):43.

    Article  PubMed  Google Scholar 

  46. Nzwalo H, Ferreira L, Peralta R, Bentes C. Sleep-related eating disorder secondary to zolpidem. BMJ Case Rep. 2013:2013.

    Google Scholar 

  47. Müller TD, Clemmensen C, Finan B, DiMarchi RD, Tschöp MH. Anti-obesity therapy: from rainbow pills to polyagonists. Pharmacol Rev. 2018;70(4):712–46.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eating Disorders Center for Treatment and Research, Department of Neuroscience, University of Turin, Turin, Italy

    Enrica Marzola, Maria Musso & Giovanni Abbate-Daga

Authors
  1. Enrica Marzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Musso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni Abbate-Daga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Abbate-Daga .

Editor information

Editors and Affiliations

  1. Private Hospital "Salus" of Ferrara, University of Ferrara, Ferrara, Italy

    Emilia Manzato

  2. Formerly Sapienza University of Rome, Founding Editor of Eating and Weight Disorders, Campiglia Marittima, Livorno, Italy

    Massimo Cuzzolaro

  3. Experimental Medicine Department, Sapienza University of Rome, Editor-in-Chief of Eating and Weight Disorders, Roma, Roma, Italy

    Lorenzo Maria Donini

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Marzola, E., Musso, M., Abbate-Daga, G. (2022). Psychotropic Drug-Induced Disordered Eating Behaviors. In: Manzato, E., Cuzzolaro, M., Donini, L.M. (eds) Hidden and Lesser-known Disordered Eating Behaviors in Medical and Psychiatric Conditions . Springer, Cham. https://doi.org/10.1007/978-3-030-81174-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-81174-7_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-81173-0

  • Online ISBN: 978-3-030-81174-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation